March 15 (Reuters) - Valeant Pharmaceuticals (NYSE:VRX) International
Inc VRX.N VRX.TO cut it revenue forecast for the year, due
to slower growth in its U.S. dermatology, gastrointestinal and
woman's health businesses.
Total revenue is expected to be $11.0 billion-$11.2 billion,
compared with its previous estimate of $12.5 billion-$12.7
billion, Valeant said on Tuesday.
Valeant, under scrutiny for its business and accounting
practices, said preliminary fourth-quarter revenue was $2.8
billion, hurt by softer-than-expected sales in its
gastrointestinal business.
The company, originally scheduled to report its
fourth-quarter results on Feb. 29, delayed the announcement and
withdrew its 2016 guidance after Chief Executive Michael Pearson (LON:PSON)
returned to office two months after he was hospitalized for
pneumonia.